Welcome to our dedicated page for NEXIMMUNE news (Ticker: NEXI), a resource for investors and traders seeking the latest updates and insights on NEXIMMUNE stock.
NexImmune, Inc. (Nasdaq: NEXI) is an emerging biopharmaceutical company focused on advancing a new generation of immunotherapies using its proprietary Artificial Immune Modulation (AIM™) technology platform. Originally developed at Johns Hopkins University, AIM™ technology harnesses the body’s immune system to orchestrate a targeted T cell response against diseases.
The cornerstone of NexImmune’s innovation is the development of artificial antigen-presenting cells (aAPCs). These aAPCs present specific antigens to T cells, which in turn stimulate a highly targeted immune response. This approach can be rapidly customized to direct immune attacks toward various foreign substances or diseased cells within the patient's body. The company is currently working on therapies aimed at treating cancer and other serious immune-mediated conditions.
NexImmune has two key product candidates in clinical trials: NEXI-001, for treating acute myeloid leukemia (AML), and NEXI-002, for multiple myeloma (MM). These candidates leverage the curative potential of the body’s own T cells, engineered to target and destroy specific cancer cells.
Recent Highlights:
Clinical and Preclinical Updates: NexImmune announced significant progress in generating pre-clinical data supporting their multi-antigen-specific T cell-directing products. This includes validation from collaborators at leading institutions, underlining the transformative potential of their AIM technology.
Financial Highlights: The company recently reported select second-quarter 2023 financial results, showcasing a focus on core capabilities while managing operational flexibility through workforce adjustments.
Partnerships: NexImmune extended its research collaboration with Yale University and JDRF. This partnership aims to explore the use of NexImmune’s AIM nanoparticles combined with anti-CD3 mAb for potential type 1 diabetes treatments. The extension includes an additional $300,000 grant provided by JDRF.
In October 2023, NexImmune executed a 1-for-25 reverse stock split, reducing its outstanding shares and addressing compliance with Nasdaq’s minimum bid price requirement. The company remains dedicated to advancing its innovative therapeutic candidates and remains a significant player in the field of immuno-oncology and beyond.
For more information, visit www.neximmune.com.
NexImmune, a clinical-stage biotechnology company, announced a collaboration with Rutgers University to develop immunotherapies targeting immune checkpoint proteins for neuroendocrine tumors. Dr. Steven K. Libutti will lead the research aimed at addressing the rising incidence of these tumors in the U.S. using NexImmune's AIM ACT platform, which employs nanoparticles to enhance T cell responses. The company is also advancing its lead candidates, NEXI-001 and NEXI-002, currently in clinical trials for treating relapsed AML and multiple myeloma.
NexImmune, a clinical-stage biotechnology company, announced CEO Scott Carmer's participation in the LLS TAP panel discussion on January 21, 2022, at 12:00 p.m. ET. The discussion focuses on advancements in next-generation cell therapies. NexImmune has received ongoing support from the Leukemia & Lymphoma Society, benefiting from investments since 2017 to enhance its Phase 1/2 studies in treating blood cancers. Their proprietary AIM™ nanoparticle technology aims to generate specific and durable immune responses, with lead programs, NEXI-001 and NEXI-002, currently in clinical trials.
NexImmune, Inc. (Nasdaq: NEXI) announces the establishment of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB), featuring notable experts in immunology and T cell biology. This strategic move aims to enhance the company's AIM nanotechnology platform, which directs antigen-specific T cells for targeted immune responses. Jerry Zeldis, EVP of R&D, emphasized the board's role in refining decisions as NexImmune expands its therapeutic pipeline, especially for its lead programs NEXI-001 and NEXI-002, both in Phase 1/2 clinical trials.
NexImmune, Inc. (Nasdaq: NEXI) announced preliminary Phase 1/2 results for NEXI-002, a novel immunotherapy for relapsed/refractory multiple myeloma presented at the 63rd ASH Annual Meeting. The study involved patients with an average of 7.6 prior therapy lines, displaying a favorable safety profile with no severe toxicities. Early data suggests NEXI-002 shows immunologic activity, with a stable disease duration of 2 to 3.5 months in patients. These results encourage ongoing evaluations and potential applications in lower-burden plasma cell dyscrasias.
NexImmune (Nasdaq: NEXI) reported a net loss of $14.6M for Q3 2021, translating to a GAAP loss per share of $0.65. Cash reserves declined to $93.2M from $102.8M in Q2 2021, expected to last through Q4 2022. The company continues to advance its Phase 1/2 trials for NEXI-001 and NEXI-002, with updates forthcoming in 2022. Collaborations with Yale University on Type 1 Diabetes using AIM INJ nanoparticles signify strategic expansion. R&D expenses surged to $11.3M, reflecting higher trial costs and personnel expenses.
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology firm, announced plans to report its third quarter financial results and provide a corporate update on November 12, 2021, before market open. The press release will be accessible on the company's investor website. NexImmune is focused on innovative immunotherapy development utilizing its AIM™ nanoparticle technology, with lead programs NEXI-001 and NEXI-002 currently in Phase 1/2 trials targeting relapsed AML and multiple myeloma, respectively.
NexImmune, a clinical-stage biotechnology company (Nasdaq: NEXI), announced that CEO Scott Carmer will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 2:00 PM ET. The event will be accessible through NexImmune's Investor Relations page, with a replay available for 90 days. NexImmune focuses on immunotherapy leveraging T cells for targeted immune responses, utilizing a proprietary AIM™ nanoparticle technology. The company’s lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 trials for relapsed AML and multiple myeloma, respectively.
NexImmune, a clinical-stage biotechnology company, announced that CEO Scott Carmer will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 1:15 p.m. ET. The chat will be available via webcast on the company's Investor Relations page, with a replay lasting 30 days. NexImmune focuses on immunotherapy using its AIM nanoparticle technology to generate targeted immune responses through T cells. Its lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 trials for treating relapsed AML and refractory multiple myeloma.
NexImmune, Inc. (NEXI) announced significant clinical developments, including its first solid tumor indication targeting HPV-associated malignancies. During Q2 2021, NexImmune reported a cash position of $102.8M, down from $118.1M in Q1. The company recorded a net loss of $12.2M, equating to a GAAP loss per share of $0.54. R&D expenses rose to $8.1M, reflecting ongoing clinical trials. The company anticipates completing enrollment in its Phase I/II trials for NEXI-001 and NEXI-002 and revealing additional data at upcoming scientific conferences.
FAQ
What is the current stock price of NEXIMMUNE (NEXI)?
What is the market cap of NEXIMMUNE (NEXI)?
What is NexImmune’s AIM™ technology?
What are NexImmune’s main product candidates?
What recent financial steps has NexImmune taken?
What are the recent clinical and preclinical highlights for NexImmune?
Which universities and organizations is NexImmune collaborating with?
What is the significance of the 1-for-25 reverse stock split?
Where can I find more information about NexImmune?
Who can be contacted for investor relations at NexImmune?
What types of diseases are NexImmune’s therapies targeting?
What potential does NexImmune’s technology hold?
